Schizophrenia

Detailed Overview

Schizophrenia severely impairs occupational and social functioning. The exact etiology is unknown, but the neurodevelopmental hypothesis suggests that disrupted brain development during early life, combined with genetic vulnerability and environmental stressors (two-hit hypothesis), leads to profound neurotransmitter dysregulation, primarily involving dopamine and glutamate pathways. Patients often lack insight into their illness (anosognosia), leading to poor treatment adherence. Lifespan is significantly reduced due to high rates of suicide and severe metabolic comorbidities exacerbated by antipsychotic medications.

Epidemiology & Demographics

Lifetime prevalence is approximately 1% globally. Peak age of onset is late adolescence to early adulthood (18-25 years for males; 25-35 years for females). Females often have a second peak in their 40s.

Etiological Mechanism

A complex interplay of genetics (polygenic inheritance involving genes like COMT, dysbindin, and C4 complement genes) and environmental factors (obstetric complications, maternal infection during pregnancy, early childhood trauma, and adolescent cannabis use).

Primary Causes

Genetic Vulnerability

Neurodevelopmental Disruption

Environmental Stressors (Cannabis use in adolescence)

• Family History: Risk is 10% for a first-degree relative and up to 50% for monozygotic twins.
• Cannabis Use: Heavy use during adolescence (particularly high-THC strains) significantly increases the risk of developing schizophrenia in vulnerable individuals.
• Paternal Age: Advanced paternal age (>50 years) is associated with an increased risk of de novo mutations.

The dopamine hypothesis posits that positive symptoms are caused by dopaminergic hyperactivity in the mesolimbic pathway (VTA to nucleus accumbens), while negative and cognitive symptoms result from dopaminergic hypoactivity in the mesocortical pathway (VTA to prefrontal cortex). The glutamate hypothesis suggests NMDA receptor hypofunction on cortical GABAergic interneurons leads to downstream disinhibition of excitatory pathways, contributing to both symptom clusters. Structural neuroimaging consistently shows enlarged lateral ventricles and cortical thinning, particularly in the superior temporal gyrus and prefrontal cortex, indicating progressive gray matter loss.

Characteristic Clinical Presentation

• Auditory Hallucinations: Hearing voices that are distinct from one's own thoughts, often derogatory or commanding.
• Delusions: Fixed, false beliefs unamenable to logic, commonly persecutory (believing one is being harmed/spied on) or grandiose.
• Disorganized Speech: Derailment, tangentiality, or word salad reflecting thought disorder.
• Alogia and Avolition: Poverty of speech and profound lack of drive to initiate goal-directed activities (Negative symptoms).

Physical Examination Signs

• Flat Affect
• Catatonia

• Suicide: Approximately 5-6% of patients die by suicide, highest risk in the period immediately following the first psychotic episode.
• Metabolic Syndrome: Severe weight gain, diabetes, and dyslipidemia secondary to second-generation antipsychotics.

Diagnostic Criteria & Guidelines

DSM-5 specifies: >= 2 core symptoms (delusions, hallucinations, disorganized speech, disorganized behavior, negative symptoms) present for a significant portion of a 1-month period. At least one must be delusions, hallucinations, or disorganized speech. Continuous signs of disturbance must persist for >= 6 months.

Differential Diagnosis

• Schizoaffective Disorder
• Bipolar Disorder with Psychotic Features
• Substance-Induced Psychotic Disorder (e.g., Methamphetamine)

Laboratory Tests & Biomarkers

• Urine Drug Screen: To rule out substance-induced psychosis (cocaine, amphetamines, PCP).
• HbA1c and Fasting Lipids: Monitored routinely, as antipsychotics severely derange these values.

Imaging Modalities & Findings

• MRI Brain:

• Prodromal Phase
  Gradual social withdrawal, odd beliefs, and decline in functioning lasting months to years before first psychosis.
• Active Phase
  Prominent positive symptoms (florid psychosis) requiring intervention.
• Residual Phase
  Positive symptoms diminish, but prominent negative and cognitive symptoms persist.

Second-Line & Adjunctive Therapy

For Treatment-Resistant Schizophrenia (failure of >= 2 adequate antipsychotic trials): Clozapine 300-600 mg PO daily. Clozapine is the most effective antipsychotic but carries strict REMS monitoring requirements due to the risk of severe agranulocytosis. Long-Acting Injectables (LAIs) like Invega Sustenna (Paliperidone) are used for non-adherence.

Surgical & Procedural Management

Not applicable. Electroconvulsive Therapy (ECT) may be used for catatonia or severe refractory psychosis.

Recommended Lifestyle Changes

• Strict avoidance of cannabis and illicit stimulants.
• Rigorous diet and exercise regimens to counteract antipsychotic-induced metabolic syndrome.

Patient Counseling & Advice

Counsel families that schizophrenia is a biological brain disease, not a moral failing. Emphasize that medication non-adherence is the primary cause of relapse, and each relapse causes further irreversible cognitive decline.

Follow-Up & Monitoring Schedule

Absolute Neutrophil Count (ANC) must be monitored weekly for the first 6 months if on Clozapine (ANC must be >= 1500/mcL). Monitor weight, BMI, BP, HbA1c, and lipid profile every 6 months for all SGAs. Assess for Tardive Dyskinesia using the AIMS scale annually.

Preventive Strategies

Early intervention in the prodromal phase (Clinical High Risk for Psychosis) with psychosocial support and omega-3 fatty acids may delay onset, but no definitive prevention exists.

Course is highly variable. ~20% have a favorable outcome and recover significantly; the majority have chronic relapsing courses with progressive functional decline. Life expectancy is reduced by 15-20 years.